This study aimed to classify endometrial cancer patients according to their MLH1 promoter methylation status instead of the POLE mutation test, as well as by their p53 and MMR status, and to correlate these classifications with clinicopathologic features, including prognosis and immune marker expression. This evidence concerns the gene POLE and endometrial cancer.